Jinli Jian
Lanzhou, 730000, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
MLN4924 promotes the transcriptional activation of BTG2 via the ROS/EGR1-mediated signaling axis to suppress acute myeloid leukemia progression.
Journal: Acta biochimica et biophysica Sinica
Published: January 07, 2026
Venetoclax combined with ML385 overcomes chemotherapy resistance in acute myeloid leukemia by modulating Nrf2/ARE-mediated oxidative stress.
Journal: Medical oncology (Northwood, London, England)
Published: August 27, 2025
Clinical Characteristics and Outcomes of Acute Myeloid Leukemia Patients Harboring NPM1/FLT3-ITD/DNMT3A Triple Mutations and the Potential Prognostic Value of GNG4.
Journal: Cancer control : journal of the Moffitt Cancer Center
Published: July 18, 2025
MLN4924 Suppresses Acute Myeloid Leukemia Progression by LINC01128-Driven Epigenetic Reactivation of TRIM58.
Journal: Drug design, development and therapy
Published: May 20, 2025
Integrated transcriptome profiling and in vitro analysis reveals MLN4924's role in inducing ferroptosis in acute myeloid leukemia.
Journal: Hematology (Amsterdam, Netherlands)
Published: May 13, 2025
Significant changes in gut microbiota and SCFAs among patients with newly diagnosed acute myeloid leukemia.
Journal: Frontiers in microbiology
Published: January 11, 2025
Comprehensive analysis of DNA methylation and gene expression to identify tumor suppressor genes reactivated by MLN4924 in acute myeloid leukemia.
Journal: Anti-cancer drugs
Published: January 09, 2025
A nomogram based on clinical features and molecular abnormalities for predicting the prognosis of patients with acute myeloid leukemia.
Journal: Translational cancer research
Published: July 12, 2023
Construction and validation of an NAD + metabolism-related lncRNA signature for predicting the prognosis and immune landscape of acute myeloid leukemia.
Journal: Hematology (Amsterdam, Netherlands)
Published: July 07, 2023
Potential applications of ferroptosis inducers and regulatory molecules in hematological malignancy therapy.
Journal: Critical reviews in oncology/hematology
Published: July 03, 2023
Development and validation of a novel prognosis prediction model for patients with myelodysplastic syndrome.
Journal: Frontiers in oncology
Published: August 08, 2022
The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis.
Journal: Hematology (Amsterdam, Netherlands)
Published: November 16, 2020
Last Updated: 09/26/2026